Cognitive behavioral therapy for adults with attention-deficit hyperactivity disorder: study protocol for a randomized controlled trial

被引:3
|
作者
Huang, Fang [1 ,2 ]
Qian, Qiujin [1 ,2 ]
Wang, Yufeng [1 ,2 ]
机构
[1] Peking Univ, Hosp 6, Natl Clin Res Ctr Mental Disorders, Inst Mental Hlth, Beijing 100191, Peoples R China
[2] Peking Univ, Minist Hlth, Key Lab Mental Hlth, Beijing 100191, Peoples R China
关键词
Attention-deficit hyperactivity disorder (ADHD); cognitive behavioral therapy (CBT); booster sessions; randomized controlled trial; MEDICATION-TREATED ADULTS; DEFICIT/HYPERACTIVITY DISORDER; RECURRENT DEPRESSION; ADHD; SYMPTOMS; QUALITY; ANXIETY; LIFE; PSYCHOTHERAPY; PREVALENCE;
D O I
10.1186/s13063-015-0686-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Attention-deficit hyperactivity disorder (ADHD) is a mental disorder beginning in childhood, and about half of patients have symptoms lasting into adulthood. Adult ADHD causes various impairments of emotional, self-esteem, and executive function and life quality aspects. Furthermore, adverse outcomes include academic and occupational failures, traffic accidents and substance abuse, which would be a family and social burden. A combination of medication and psychotherapy is recommended as the treatment for adult ADHD, and cognitive behavioral therapy (CBT) has been validated mostly with evidence-based researches. However, there has been a lack of randomized controlled trials of CBT for patients in China. Moreover, booster sessions of CBT for other disorders have proven effective in reducing recurrence and improving long-term outcomes, which has not been investigated for adult ADHD. This study will testify to the effect of CBT and explore the efficacy of subsequent booster sessions on adult ADHD. Methods/Design: It is a three-armed randomized controlled trial to evaluate the efficacy of 12 weeks of CBT based on the published and validated manual and its booster sessions. The 12 weeks of CBT will be conducted weekly and will end at the 12th week, and then the booster sessions will be conducted monthly and end at the 24th week. There are three randomized groups, including a CBT with booster sessions group, a CBT group and a waiting group. Participants are outpatients of the Peking University Sixth Hospital who are diagnosed as having adult ADHD. The Primary efficacy endpoints are the scores of ADHD core symptoms at 12 and 24 weeks. Secondary endpoints include emotion, executive function, self-esteem, life quality and functional magnetic resonance imaging (fMRI) data at different time points, and the change within every group will also be analyzed. Discussion: This is the first study to explore the efficacy of booster sessions of CBT in adult ADHD as far as we know. The results might increase proof of efficacy of CBT for adult ADHD in China, and the results showing efficacy of the booster sessions would also benefit our clinical practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Homeopathy for attention-deficit/hyperactivity disorder: A pilot randomized-controlled trial
    Jacobs, J
    Williams, AL
    Girard, C
    Njike, VY
    Katz, D
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2005, 11 (05) : 799 - 806
  • [32] Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder
    Wilens, TE
    Biederman, J
    Spencer, TJ
    Frazier, J
    Prince, J
    Bostic, J
    Rater, M
    Soriano, J
    Hatch, M
    Sienna, M
    Millstein, RB
    Abrantes, A
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (03) : 257 - 264
  • [33] Drug therapy for adults with attention-deficit hyperactivity disorder
    Wilens, TE
    DRUGS, 2003, 63 (22) : 2395 - 2411
  • [34] Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study
    Wilens, TE
    Haight, BR
    Horrigan, JP
    Hudziak, JJ
    Rosenthal, NE
    Connor, DF
    Hampton, KD
    Richard, NE
    Modell, JG
    BIOLOGICAL PSYCHIATRY, 2005, 57 (07) : 793 - 801
  • [35] Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled clinical trial
    Riahi, Forough
    Tehrani-Doost, Mehdi
    Shahrivar, Zahra
    Alaghband-Rad, Javad
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2010, 25 (7-8) : 570 - 576
  • [36] Randomized Controlled Trial of Osmotic-Release Methylphenidate With Cognitive-Behavioral Therapy in Adolescents With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders
    Riggs, Paula D.
    Winhusen, Theresa
    Davies, Robert D.
    Leimberger, Jeffrey D.
    Mikulich-Gilbertson, Susan
    Klein, Constance
    Macdonald, Marilyn
    Lohman, Michelle
    Bailey, Genie L.
    Haynes, Louise
    Jaffee, William B.
    Haminton, Nancy
    Hodgkins, Candace
    Whitmore, Elizabeth
    Trello-Rishel, Kathlene
    Tamm, Leanne
    Acosta, Michelle C.
    Royer-Malvestuto, Charlotte
    Subramaniam, Geetha
    Fishman, Marc
    Holmes, Beverly W.
    Kaye, Mary Elyse
    Vargo, Mark A.
    Woody, George E.
    Nunes, Edward V.
    Liu, David
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2011, 50 (09): : 903 - 914
  • [37] Dialectical behavioral therapy-based group treatment versus treatment as usual for adults with attention-deficit hyperactivity disorder: a multicenter randomized controlled trial
    Halmoy, Anne
    Ring, Anna Edith
    Gjestad, Rolf
    Moller, Merete
    Ubostad, Bente
    Lien, Tage
    Munkhaugen, Ellen Kathrine
    Fredriksen, Mats
    BMC PSYCHIATRY, 2022, 22 (01)
  • [38] Dialectical behavioral therapy-based group treatment versus treatment as usual for adults with attention-deficit hyperactivity disorder: a multicenter randomized controlled trial
    Anne Halmøy
    Anna Edith Ring
    Rolf Gjestad
    Merete Møller
    Bente Ubostad
    Tage Lien
    Ellen Kathrine Munkhaugen
    Mats Fredriksen
    BMC Psychiatry, 22
  • [40] Attention-deficit hyperactivity disorder in adults
    Wender, PH
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 1998, 21 (04) : 761 - +